[어닝콜] Schrödinger targets adjusted EBITDA surplus by 2026, converts hosting ratio to 75%
2026.03.23 18:07 Business/Investment Plan
AI analytics
Schrödinger (SDGR) presented meaningful indicators such as a 100% customer retention rate and $200 million in annual sales, but it stands out for its tendency to rely on qualitative optimism without a timeframe for achieving EBITDA surplus or a specific EPS target. The 75% hosting conversion plan is positive, but the implementation roadmap is unclear, and direct answers to sensitive issues such as margin pressure were not confirmed in the Q&A, so potential risks have not been completely resolved. A short-term neutral to slightly positive impact on the stock price is expected, but there is insufficient numerical evidence to consider it as a strong basis for purchase.
Schrödinger reveals long-term strategy based on computational platform at KeyBanc forum
Present status of 100% customer retention rate and annual sales of approximately $200 million
Announcement of conversion of 75% of hosting contracts and EBITDA surplus goal by 2026
Essential tooling and 100% customer retention rate in an AI-based drug discovery platform
Schrodinger (SDGR) unveiled its strategy to expand its presence in the pharmaceutical industry, emphasizing the differentiated competitiveness of its computational drug discovery platform at the KeyBanc Capital Markets Healthcare Virtual Forum.
CEO Rami Farid highlighted the fact that the company achieved results in unique molecular design based on technology accumulated over 15 years. He said, “It is the only platform that has innovatively improved the time and resource waste of existing drug discovery methods,” and added, “The customer retention rate of 100% proves the quality and reliability of the product.”
What is particularly noteworthy is that pharmaceutical companies are beginning to recognize the Schrödinger platform as an essential tool. CEO Farid expressed confidence in strengthening the company’s positioning in the market, saying, “Our platform, which helps researchers efficiently design better molecules, is now becoming an indispensable element in the pharmaceutical development process.”
In the field of predicted toxic products, growth potential is also increasing by securing a new budget. “We will achieve amazing results with our new toxicity prediction solution,” Farid said, also mentioning plans for further innovation in computational drug discovery through the combination of AI.
Target to turn profitable by 2026, secure revenue stability by converting 75% of hosting contracts
CFO Rich Jan presented a detailed roadmap for improving the financial structure and achieving profitability. He emphasized that he is focusing on cost efficiency, saying, “We are aiming to achieve an adjusted EBITDA surplus by 2026 by simplifying the corporate structure.”
Transformation of the software business model has also emerged as a key strategy. CFO Jan explained, “We plan to increase the hosting contract ratio to approximately 75% by 2026,” adding, “This is a strategy to increase profit stability by establishing a recurring and predictable sales structure.”
Schrödinger, which currently has annual sales of approximately $200 million, is also active in launching new products and expanding the market. CFO Jan predicted, “Our existing customer base is highly loyal and demand for new products is solid,” and “As the transition to a hosting model accelerates, we will be able to secure stable cash flow based on long-term contracts.”
The company’s stance is to maintain a selective approach to mergers and acquisitions (M&A). The management showed a cautious attitude, saying, “We will review it only when necessary, but we are keeping in mind the supplementation of technology appropriate for market changes.”
Analyst Q&A, focusing on predictive toxicity solutions and AI strategies
In the Q&A session, analyst Scott Schoenhaus asked about future strategies and ways to respond to market changes. CEO Farid pointed out the predicted toxicity product field as the target of intensive targeting and responded, “We are increasing our growth potential by securing a new budget.”
What management emphasized most was technological innovation through combination with AI. Farid said, “We will pursue continuous technological advancement while meeting customer needs,” and presented a vision that “AI-based computational drug discovery will become an industry standard.”
Instead of avoiding a clear answer to M&A-related questions, the company reaffirmed its principled position of “reviewing only when technological supplementation is necessary.” This is interpreted as a determination to focus on the current organic growth strategy.
Analysts were positive about the company’s goals of 100% customer retention and 75% hosting conversion rate, but asked for more information about when adjusted EBITDA surplus would be achieved and specific milestones. Management suggested 2026 as a financial turning point, saying, “We are confident that we will achieve our goal as structural improvement and sales growth are progressing simultaneously.”
😊 I’m positive
- 100% customer retention rate: This is a key indicator that proves the actual lock-in of the software platform and supports sales stability.
- Hosting contract conversion: 75% by 2026 Hosting contract conversion is a structural change that will increase revenue visibility by increasing the proportion of recurring subscription revenue.
- Based on annual sales of $200 million: This figure provides investor confidence in the scale of the business by presenting specific sales volume.
🥶 It’s negative.
- Absence of numerical guidance: There is concern about optimism bias as it is limited to qualitative expressions without specific financial figures such as when EBITDA surplus will be achieved and EPS target.
- Toxicity prediction product overconfidence: Executive statements that ‘we will deliver amazing results’ are a deceptive language pattern of overconfidence without verified data.
- Lack of in-depth Q&A discussion: Doubts remain unresolved as no specific responses to sensitive issues such as analyst re-questions or margin pressure have been confirmed.
View latest performance